Astria Therapeutics — Merger or Acquisition (October 2025)
11 slides from Astria Therapeutics's merger presentation, Oct 14, 2025
Slide 1: Investor Presentation October 2025
Investor Presentation October 2025 1 Confidential
Slide 2: Important Additional Information will be Filed with the SEC
2 Important Additional Information will be Filed with the SEC In connection with the proposed transaction, BioCryst Pharmaceuticals, Inc. (“BioCryst”) will file with the U.S. Securities a nd Exchange Commission (the “SEC”) a registration statement on Form S - 4 (the “registration statement”), which
Slide 3: Forward-looking statements
Forward - looking statements 3 Statements included in this communication which are not historical in nature or do not relate to current facts are intended t o b e, and are hereby identified as, forward - looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act
Slide 4: BioCryst and Astria: Establishing a Leading HAE Company
• With the addition of navenibart, BioCryst’s portfolio will include both a leading oral and potentially best - in - class injectable therapy for HAE, empowering physicians and patients with optimal choices for individualized care Expands Patient Options in HAE • BioCryst’s established commercializa
Slide 5: BioCryst's commercial footprint primed for next product
BioCryst’s commercial footprint primed for next product 5 Commercial strategy for ORLADYEO is a repeatable playbook for navenibart Patients & HAEA Physicians & KOLs Single source specialty pharmacy Payers x Robust market understanding through market research, data, and insights Deep understanding of
Slide 6: Navenibart could become the first choice injectable therapy
Navenibart could become the 1 st choice injectable therapy 6 30% 40% 50% 60% 70% 80% 90% 100% 0 4 8 12 16 20 24 28 Mean Attack Rate Reduction Dosing Interval (weeks) (Q8W) (Q4W) x Trusted mechanism & modality Monoclonal antibody inhibitor of plasma kallikrein x Compelling efficacy data High affinity
Slide 7: BioCryst's commercial footprint primed for next product
BioCryst’s commercial footprint primed for next product 7 Commercial strategy for ORLADYEO is a repeatable playbook for navenibart Patients & HAEA Physicians & KOLs Single source specialty pharmacy Payers x Robust market understanding through market research, data, and insights Deep understanding of
Slide 8: Positioned to Optimally Serve the HAE Community
COLI LIVING WITH HA E 8 Positioned to Optimally Serve the HAE Community • Potential for complementary HAE programs – once daily oral and long - acting injectable o BioCryst’s ORLADEYO , the first - ever oral preventative therapy for HAE o Astria’s navenibart , an innovative investigational long - ac
Slide 9: Continuing Momentum Through Close
ALPHA - ORBIT pivotal Phase 3 trial remains on - track to deliver top - line results in early 2027 ORBIT - EXPANSE long - term Phase 3 trial is actively enrolling ALPHA - ORBIT roll - over participants CMC and device work remains on - track to launch navenibart with both auto - injector and pre - fi
Slide 10: Significant opportunity for value creation
Significant opportunity for value creation 10 Financial overview of the acquisition of Astria • Implied value of $13 per share in cash and stock with total enterprise value of approximately $700 million • Astria stockholders expected to own 15% of proforma equity based on basic shares outstanding •
Slide 11: Slide 11
Astria Therapeutics — Merger or Acquisition (October 2025) on 6ix